216 related articles for article (PubMed ID: 28608024)
1. Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.
Dell'Oro R; Maloberti A; Nicoli F; Villa P; Gamba P; Bombelli M; Mancia G; Grassi G
High Blood Press Cardiovasc Prev; 2017 Dec; 24(4):393-400. PubMed ID: 28608024
[TBL] [Abstract][Full Text] [Related]
2. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
Dore FJ; Domingues CC; Ahmadi N; Kundu N; Kropotova Y; Houston S; Rouphael C; Mammadova A; Witkin L; Khiyami A; Amdur RL; Sen S
Cardiovasc Diabetol; 2018 May; 17(1):65. PubMed ID: 29724198
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
4. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin + metformin. Mostly disadvantages.
Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
[No Abstract] [Full Text] [Related]
6. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I;
Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286
[TBL] [Abstract][Full Text] [Related]
7. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Fonseca V; Zhu T; Karyekar C; Hirshberg B
Diabetes Obes Metab; 2012 Apr; 14(4):365-71. PubMed ID: 22192246
[TBL] [Abstract][Full Text] [Related]
8. Saxagliptin (Onglyza) for type 2 diabetes.
Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
[No Abstract] [Full Text] [Related]
9. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.
Tomiyama H; Miwa T; Kan K; Matsuhisa M; Kamiya H; Nanasato M; Kitano T; Sano H; Ohno J; Iida M; Sata M; Yamada H; Maemura K; Tanaka A; Murohara T; Node K
Cardiovasc Diabetol; 2016 Nov; 15(1):150. PubMed ID: 27809848
[TBL] [Abstract][Full Text] [Related]
10. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
[TBL] [Abstract][Full Text] [Related]
12. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
13. Determinants of vascular function in patients with type 2 diabetes.
Naka KK; Papathanassiou K; Bechlioulis A; Kazakos N; Pappas K; Tigas S; Makriyiannis D; Tsatsoulis A; Michalis LK
Cardiovasc Diabetol; 2012 Oct; 11():127. PubMed ID: 23062182
[TBL] [Abstract][Full Text] [Related]
14. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Kitao N; Miyoshi H; Furumoto T; Ono K; Nomoto H; Miya A; Yamamoto C; Inoue A; Tsuchida K; Manda N; Kurihara Y; Aoki S; Nakamura A; Atsumi T;
Cardiovasc Diabetol; 2017 Oct; 16(1):125. PubMed ID: 29017497
[TBL] [Abstract][Full Text] [Related]
15. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson JG; Hellqvist Å; Gause-Nilsson I
Int J Clin Pract; 2013 Apr; 67(4):307-16. PubMed ID: 23638466
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
17. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
[TBL] [Abstract][Full Text] [Related]
19. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
[No Abstract] [Full Text] [Related]
[Next] [New Search]
